Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/3567
Full metadata record
DC FieldValueLanguage
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva-
dc.contributor.authorInstituto Nacional de Câncer (Brasil)-
dc.contributor.authorINCA-
dc.contributor.authorSistema Único de Saúde (Brasil)-
dc.contributor.authorBrasil. Ministério da Saúde-
dc.date.accessioned2021-08-03T15:31:02Z-
dc.date.available2021-08-03T15:31:02Z-
dc.date.issued2020-07-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/3567-
dc.description3 p.: tab. p&b.-
dc.language.isootherpt_BR
dc.publisherINCApt_BR
dc.relation.ispartofseriesAno IV, n. 39.-
dc.subjectAnticorpos Antineoplásicospt_BR
dc.subjectAntibodies, Neoplasmpt_BR
dc.subjectGenes erbB-2-
dc.subjectGenes, erbB-2-
dc.subjectPertuzumabe-
dc.subjectAnticuerpos Antineoplásicos-
dc.titleDistribuição do pertuzumabept_BR
dc.TypeRevistas/Boletinspt_BR
Appears in Collections:Informe SUS - ONCO 2020

Files in This Item:
File Description SizeFormat 
Informe-sus-onco-Julho-2020.pdf460.66 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.